141 related articles for article (PubMed ID: 6197164)
1. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Camiolo SM; Markus G; Englander LS; Siuta MR; Hobika GH; Kohga S
Cancer Res; 1984 Jan; 44(1):311-8. PubMed ID: 6197164
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
Markus G; Camiolo SM; Kohga S; Madeja JM; Mittelman A
Cancer Res; 1983 Nov; 43(11):5517-25. PubMed ID: 6193874
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators in human malignant melanoma.
Markus G; Kohga S; Camiolo SM; Madeja JM; Ambrus JL; Karakousis C
J Natl Cancer Inst; 1984 Jun; 72(6):1213-22. PubMed ID: 6374238
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator content of neoplastic and benign human prostate tissues; fibrin augmentation of an activator activity.
Camiolo SM; Markus G; Evers JL; Hobika GH; DePasquale JL; Beckley S; Grimaldi JP
Int J Cancer; 1981 Feb; 27(2):191-8. PubMed ID: 6169657
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
9. [Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer].
Pflüger H; Kirchheimer J; Ritschl P; Köller A; Hienert G; Binder BR
Wien Klin Wochenschr; 1984 Sep; 96(17):658-61. PubMed ID: 6083673
[TBL] [Abstract][Full Text] [Related]
10. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
[TBL] [Abstract][Full Text] [Related]
11. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
Wilson MJ; Ludowese C; Sinha AA; Estensen RD
Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
[TBL] [Abstract][Full Text] [Related]
12. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.
Holmberg L; Kristoffersson AC; Lecander I; Wallén P; Astedt B
Scand J Clin Lab Invest; 1982 Jun; 42(4):347-54. PubMed ID: 6753100
[TBL] [Abstract][Full Text] [Related]
13. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Kohga S; Harvey SR; Weaver RM; Markus G
Cancer Res; 1985 Apr; 45(4):1787-96. PubMed ID: 3884145
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
Wilson MJ; Sinha AA
Cell Mol Biol Res; 1993; 39(8):751-60. PubMed ID: 7951414
[TBL] [Abstract][Full Text] [Related]
15. Immunological characterization of plasminogen activator activities in human tissues and body fluids.
Rijken DC; Wijngaards G; Welbergen J
J Lab Clin Med; 1981 Apr; 97(4):477-86. PubMed ID: 6782183
[TBL] [Abstract][Full Text] [Related]
16. Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
Wilson EL; Becker ML; Hoal EG; Dowdle EB
Cancer Res; 1980 Mar; 40(3):933-8. PubMed ID: 7193517
[TBL] [Abstract][Full Text] [Related]
17. Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue.
Shih SJ; Dall'Era MA; Westphal JR; Yang J; Sweep CG; Gandour-Edwards R; Evans CP
Prostate Cancer Prostatic Dis; 2003; 6(2):131-7. PubMed ID: 12806371
[TBL] [Abstract][Full Text] [Related]
18. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
19. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Cozzi PJ; Wang J; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y
Hum Pathol; 2006 Nov; 37(11):1442-51. PubMed ID: 16949925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
